Answers are grounded in this paper and cite their sources.
Randomized trial demonstrates pharmacokinetic equivalence between biosimilar Bmab-1200 and reference ustekinumab in healthy subjects, indicating comparable clinical profiles.
BACKGROUND: This study assessed the pharmacokinetics (PK) equivalence, safety, tolerability, and immunogenicity of Bmab-1200 versus the reference product ustekinumab (EU-approved and US-licensed Stelara). RESEARCH DESIGN & METHODS: . Secondary endpoints included additional PK parameters, immunogenicity, and safety and tolerability. RESULTS: (90% CIs of the GLSM ratio: 0.9478-1.0732, 0.9136-1.0376, and 0.9012-1.0267, respectively). All secondary analyses supported the primary results. CONCLUSION: Three-way PK equivalence between Bmab-1200, US-Stelara, and EU-Stelara was demonstrated. A single, 45-mg dose of Bmab-1200 was safe and well tolerated, and, overall, the number of AEs was similar among the groups. Diversity limited to White and Japanese groups did not impact the study results. CLINICAL TRIAL REGISTRATION: This study was registered with www.isrctn.com; identifier: ISRCTN11424009.
No takes yet. Share an insight, caveat, or question.
Ackroyd et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: